Alejo Rodriguez-Vida

8PUBLICATIONS
86CO-AUTHORS
Immunogenetics (incl. genetic immunology)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Oct 15, 2026
Immune checkpoint inhibitor-related myocarditis, myositis, and myasthenia gravis overlap syndrome: a single-center case series and systematic review.

|Jan 09, 2026
Uncovering the role of ETS2 in prostate cancer pathogenesis: relationship with p53 and ERG.

Laura Segalés, Nuria Juanpere, Marta Lorenzo

|Oct 30, 2024
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma.

Aude Fléchon, Rafael Morales-Barrera, Thomas Powles

|Nov 28, 2023
Immunohistochemical markers as predictors of prognosis in multifocal prostate cancer.

Laura Segalés, Nuria Juanpere, Nerea Gallarín

|May 10, 2023
A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors.

Ignacio Melero, Tamara Tanos, Mariana Bustamante

|Feb 25, 2023
Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma.

Pauline Parent, Edouard Auclin, Anna Patrikidou

Pageof 2

Frequent Collaborators

3 joint publications

Joaquim Bellmunt

2 joint publications

Lluís Cechinni

2 joint publications

Thomas Powles

2 joint publications

Lluís Fumadó